Skip to main content

Table 3 HCV PCR of the studied group at weeks 24 and 36 of DAA therapy

From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus

PCR

Week 0

Week 24 (SVR 12)

Week 36 (SVR24)

N

%

N

%

N

%

Positive

50

100.00

2

4.00

4

8.00

Negative

0

0.00

48

96.00

46

92

Total

50

100.00

50

100.00

50

100.00